C7, one of the components of the terminal complement complex (TCC), also know as the membrane attack complex (MAC).
Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 MAC.
This complex is assembled from five precursor molecules in the serum, finalized with the polymerization of C9 which accompanies insertion of the complex into the cell membrane causing cellular lysis.
C7 occupies an important position in the TCC cascade.
C7 undergoes a hydrophilic-amphiphilic transition following activation.
It enables the developing MAC to bind directly to target cell membranes.
C7 has been shown to exhibit genetic polymorphism.
Polymorphonuclear leukocytes represent a major source of C7.
The fact that inflammatory cells have the potential to secrete C7 suggests an important role for locally produced complement in the inflammatory process.
Applications:Suitable for use in Peptide ELISA and Western Blot.
Other applications not tested.
Recommended Dilution:Peptide ELISA: 1:128,000Western Blot: 0.1-0.3ug/mlOptimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Aliquots are stable for 12 months.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
Host：goat
Source Antibody：human
Grade：Affinity Purified
Purity：Purified by immunoaffinity chromatography.
Form：Supplied as a liquid in Tris saline, pH 7.3, 0.5% BSA, 0.02% sodium azide.
Specificity：Recognizes human C7.
Isotype：IgG
Calc Applications Abbrev：E WB
Calc Crossreactivity：Hu
Immunogen：Synthetic peptide corresponding to C-NELTGQFRNRVINTK, from the internal region of the protein sequence according to NP_000578.2.
